Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087

Author:

Chen Robert1,Zinzani Pier Luigi2,Lee Hun Ju3,Armand Philippe4,Johnson Nathalie A.5,Brice Pauline6,Radford John7,Ribrag Vincent8,Molin Daniel9,Vassilakopoulos Theodoros P.10,Tomita Akihiro11,von Tresckow Bastian12,Shipp Margaret A.4,Lin Jianxin13,Kim Eunhee13,Nahar Akash13,Balakumaran Arun13,Moskowitz Craig H.14

Affiliation:

1. Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA;

2. Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology “Seràgnoli” University of Bologna, Bologna, Italy;

3. Department of Lymphoma and Myeloma, The University of Texas, MD Anderson Cancer Center, Houston, TX;

4. Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA;

5. Department of Hematology, Jewish General Hospital, Montreal, QC, Canada;

6. Department of Hematology-Oncology, Hopital Saint Louis, Paris, France;

7. Division of Cancer Sciences, The University of Manchester and The Christie NHS Foundation Trust, Manchester, United Kingdom;

8. Department of Drug Development and Hematology, Institut Gustave Roussy, Villejuif, France;

9. Section of Experimental and Clinical Oncology, Department of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden;

10. Department of Hematology and Bone Marrow Transplantation, General Hospital of Athens, Athens, Greece;

11. Department of Hematology, Fujita Health University School of Medicine, Toyoake, Japan;

12. Department of Internal Medicine, University of Cologne and University Hospital of Cologne, Cologne, Germany;

13. Medical Oncology, Merck & Co, Inc, Kenilworth, NJ; and

14. Department of Medicine, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL

Abstract

Abstract Chen and colleagues report excellent durability of response at 2 years for patients responding to pembrolizumab for relapsed Hodgkin lymphoma.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Cited by 267 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3